Oral IL-23 receptor antagonist for psoriasis promising: Phase 2b studyJuly 11, 2023PsoriasisPsoriatic Arthritis
Study finds subcutaneous spesolimab reduces flares in patients with GPPJuly 11, 2023PsoriasisPsoriatic Arthritis
For psoriasis, review finds several biosimilars as safe and effective as biologicsJune 30, 2023PsoriasisPsoriatic ArthritisBusiness of Medicine
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?June 30, 2023Psoriatic ArthritisPsoriasis
Methotrexate does not impair sperm quality, small study findsJune 21, 2023Psoriatic ArthritisPsoriasis
After Yusimry’s steep discount, little clarity on future adalimumab biosimilar pricingJune 16, 2023Business of MedicinePsoriatic ArthritisPediatricsPsoriasis
EULAR PsA recommendations update emphasizes safety, nonmusculoskeletal manifestationsJune 9, 2023Psoriatic Arthritis
Cell activity in psoriasis may predict disease severity and provide clues to comorbiditiesJune 7, 2023PsoriasisPsoriatic Arthritis
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitisJune 1, 2023Atopic DermatitisContact DermatitisPsoriatic Arthritis
ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDsJune 1, 2023Psoriatic Arthritis
FDA approves Yuflyma as ninth adalimumab biosimilarMay 24, 2023Psoriatic ArthritisPediatricsRare DiseasesPsoriasis
FDA approves autoinjector pen for Humira biosimilar, CyltezoMay 24, 2023PediatricsPsoriatic ArthritisRare DiseasesPsoriasis
MACE, VTE rates compared between TNF and JAK inhibitors for AxSpA and PsAMay 19, 2023Psoriatic Arthritis
